Quick Answer
Transcode Therapeutics, Inc. reported Shares Outstanding of 1.03 million shares for fiscal year 2024.
Transcode Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2024 | 1.03M | +5312.3% |
| 2023 | 19,014 | +17.2% |
| 2022 | 16,222 | -99.9% |
| 2021 | 12.90M | +178.3% |
| 2020 | 4.64M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 833,683 | -95.2% | +0.0% |
| June 30, 2025 | 833,683 | -88.5% | -96.4% |
| March 31, 2025 | 23.34M | +301.9% | +63408.7% |
| December 31, 2024 | 36,753 | -94.1% | -99.8% |
| September 30, 2024 | 17.27M | +61.5% | +137.6% |
| June 30, 2024 | 7.27M | +272.5% | +25.1% |
| March 31, 2024 | 5.81M | -63.3% | +825.7% |
| December 31, 2023 | 627,448 | -3.3% | -94.1% |
- Transcode Therapeutics, Inc. showed an increase of +5312.3% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2024 period, Transcode Therapeutics, Inc.’s shares outstanding has declined by 77.8% (from 4.64 million shares to 1.03 million shares).
- The most recent figure is from Transcode Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: